Search

Displaying results 5481 - 5490 of 10000 in total
  1. Drug

    IGN311

    go.drugbank.com/drugs/DB04988
    Experimental

    IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.

  2. Drug

    Eniporide

    go.drugbank.com/drugs/DB20221
    Experimental

    Eniporide is a small molecule drug. The usage of the INN stem '-poride' in the name indicates that Eniporide is a Na+/H+ antiport inhibitor. Eniporide has a monoisotopic molecular weight of 320.09 Da.

  3. Drug

    Zoniporide

    go.drugbank.com/drugs/DB20312
    Experimental

    Zoniporide is a small molecule drug. The usage of the INN stem '-poride' in the name indicates that Zoniporide is a Na+/H+ antiport inhibitor. … Zoniporide has a monoisotopic molecular weight of 320.14 Da.

  4. Drug

    Descartes-30

    go.drugbank.com/drugs/DB16361
    Investigational

    [L27531] The RNA-engineering is performed with Cartesian Therapeutics’ proprietary RNA Armory which is a platform that activates and provides cells with mRNA-based therapeutics. … Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics.

  5. Drug

    PEV3A

    go.drugbank.com/drugs/DB05144
    Investigational

    PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. … The elicited antibodies are highly specific and able to inhibit the parasite’s ability to invade liver tissue _in vitro_.

  6. Drug

    Razaxaban

    go.drugbank.com/drugs/DB19834
    Experimental

    Razaxaban is a small molecule drug. The usage of the INN stem '-xaban' in the name indicates that Razaxaban is a blood coagulation factor XA​ inhibitor, antithrombotic. … Razaxaban has a monoisotopic molecular weight of 528.16 Da.

  7. Drug

    AM336

    go.drugbank.com/drugs/DB06563
    Experimental

    It was investigated as a potential treatment for various pain conditions. … Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.

    Categories: Calcium Channels, N-Type
  8. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. … moderate-to-severe asthma), NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in

  9. Drug

    Meticrane

    go.drugbank.com/drugs/DB13284
    Approved

    Meticrane is a diuretic medication. It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].

  10. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor. … It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase